866-997-4948(US-Canada Toll Free)

Bladder Carcinoma - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Dec 2013

Category :

Oncology

No. of Pages : 38 Pages


Global Markets Directs, \'Bladder Carcinoma Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Bladder Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bladder Carcinoma. Bladder Carcinoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Bladder Carcinoma.
  • A review of the Bladder Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Bladder Carcinoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Bladder Carcinoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Bladder Carcinoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Bladder Carcinoma Overview 6
Therapeutics Development 7
Pipeline Products for Bladder Carcinoma - Overview 7
Pipeline Products for Bladder Carcinoma - Comparative Analysis 8
Bladder Carcinoma - Therapeutics under Development by Companies 9
Bladder Carcinoma - Therapeutics under Investigation by Universities/Institutes 10
Bladder Carcinoma - Pipeline Products Glance 11
Early Stage Products 11
Bladder Carcinoma - Products under Development by Companies 12
Bladder Carcinoma - Products under Investigation by Universities/Institutes 13
Bladder Carcinoma - Companies Involved in Therapeutics Development 14
Genmab A/S 14
TheRyte Ltd. 15
Bioncotech Therapeutics S.L. 16
Tolero Pharmaceuticals, Inc. 17
Bladder Carcinoma - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Molecule Type 23
Assessment by Therapeutic Class 25
Drug Profiles 27
BO-110 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
TP-3654 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecule to Inhibit TYRO-3 for Bladder Carcinoma - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Antibody to Inhibit TYRO-3 for Bladder Carcinoma - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
RNAi to Inhibit TYRO-3 for Bladder Carcinoma - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Soluble Bait to Inhibit TYRO-3 for Bladder Carcinoma - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
TF-011-Monomethyl Auristatin E - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
THR-53 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Bladder Carcinoma - Dormant Projects 36

Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 38
Disclaimer 38

List of Table


Number of Products under Development for Bladder Carcinoma, H2 2013 7
Number of Products under Development for Bladder Carcinoma - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Early Stage Development, H2 2013 11
Products under Development by Companies, H2 2013 12
Products under Investigation by Universities/Institutes, H2 2013 13
Bladder Carcinoma - Pipeline by Genmab A/S, H2 2013 14
Bladder Carcinoma - Pipeline by TheRyte Ltd., H2 2013 15
Bladder Carcinoma - Pipeline by Bioncotech Therapeutics S.L., H2 2013 16
Bladder Carcinoma - Pipeline by Tolero Pharmaceuticals, Inc., H2 2013 17
Assessment by Monotherapy Products, H2 2013 18
Number of Products by Stage and Target, H2 2013 20
Number of Products by Stage and Mechanism of Action, H2 2013 22
Number of Products by Stage and Molecule Type, H2 2013 24
Number of Products by Stage and Therapeutic Class, H2 2013 26
Bladder Carcinoma - Dormant Projects, H2 2013 36

List of Chart


Number of Products under Development for Bladder Carcinoma, H2 2013 7
Number of Products under Development for Bladder Carcinoma - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Early Stage Products, H2 2013 11
Assessment by Monotherapy Products, H2 2013 18
Number of Products by Top 10 Target, H2 2013 19
Number of Products by Stage and Top 10 Target, H2 2013 20
Number of Products by Top 10 Mechanism of Action, H2 2013 21
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 22
Number of Products by Top 10 Molecule Type, H2 2013 23
Number of Products by Stage and Top 10 Molecule Type, H2 2013 24
Number of Products by Top 10 Therapeutic Class, H2 2013 25
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 26

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *